Pharmacokinetic interactions with rifampicin : clinical relevance.

@article{Niemi2003PharmacokineticIW,
  title={Pharmacokinetic interactions with rifampicin : clinical relevance.},
  author={Mikko T. Niemi and Janne T. Backman and Martin F. Fromm and Pertti J Neuvonen and Kari T. Kivist{\"o}},
  journal={Clinical pharmacokinetics},
  year={2003},
  volume={42 9},
  pages={819-50}
}
The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes, having the greatest effects on the expression of cytochrome P450 (CYP) 3A4 in the liver and in the small intestine. In addition, rifampicin induces some drug transporter proteins, such as intestinal and hepatic P-glycoprotein. Full induction of drug-metabolising enzymes is reached in about 1 week after starting rifampicin treatment and the induction dissipates in roughly 2 weeks after discontinuing… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 210 extracted citations

Similar Papers

Loading similar papers…